[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350896-105":59,"doc-detail-350896-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cisplatin-as-a-xenobiotic-agent-molecular-mechanisms-of-actions-and-clinical-applications-in-oncology","Cisplatin as a Xenobiotic Agent - Molecular Mechanisms of Actions and Clinical Applications in Oncology","","Cisplatin is a platinum-based cornerstone of modern chemotherapy, widely used against diverse solid tumors, with anticancer effects driven mainly by DNA crosslinks that block replication and repair, ultimately triggering apoptosis. Its clinical value is limited by cisplatin toxicity, stemming from interactions with tumor DNA as well as proteins and nucleic acids in healthy tissues, producing nephrotoxicity, ototoxicity, neurotoxicity, and gastrointestinal injury. Resistance mechanisms include reduced drug accumulation, enhanced DNA repair, thiol-mediated detoxification, and apoptotic signaling alterations, so outcomes often require alternative or combination strategies. The review covers cisplatin chemistry, cytotoxicity and resistance mechanisms, oncology applications, and clinical complications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cisplatin-as-a-xenobiotic-agent-molecular-mechanisms-of-actions-and-clinical-applications-in-oncology/350896/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cisplatin-as-a-xenobiotic-agent-molecular-mechanisms-of-actions-and-clinical-applications-in-oncology/350896.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes cisplatin effective against cancer cells?","Question",{"text":112,"@type":113},"Cisplatin forms DNA crosslinks that obstruct DNA replication and repair, leading to apoptosis. This underpins its frontline use in chemotherapy regimens.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the major clinical limitations of cisplatin?",{"text":117,"@type":113},"Its toxicity and the development of resistance. Toxicity involves damage to healthy tissues through interactions with proteins and nucleic acids, causing nephrotoxicity, ototoxicity, neurotoxicity, and gastrointestinal injury.",{"name":119,"@type":110,"acceptedAnswer":120},"How do tumor cells develop resistance to cisplatin?",{"text":121,"@type":113},"Tumors can reduce intracellular drug accumulation, enhance DNA repair, detoxify cisplatin using thiol-containing molecules, or alter apoptotic signaling. These pathways compromise treatment outcomes and may require alternative or combination strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350896,1790480746,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Review  \nCisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology  \nMonia Cecati 1,†, Valentina Pozzi 2,†, Veronica Pompei 2, Valentina Schiavoni 2, Stefania Fumarola 3, Alice Romagnoli 4, Giovanni Tossetta 1, *, Angelo Montana 5, Alessandro Polizzi 6, Davide Sartini 2,‡ and Roberto Campagna 1, *,‡  \nAcademic Editor: WeiminGao  \nReceived: 10 November 2025  \nRevised: 22 December 2025  \nAccepted: 6 January 2026  \nPublished: 8 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy; [monia.cecati@uniroma5.it](monia.cecati@uniroma5.it)  \n2 Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy;  \n[v.pozzi@univpm.it](v.pozzi@univpm.it) (V.P.); [v.pompei@univpm.it](v.pompei@univpm.it) (V.P.); [v.schiavoni@pm.univpm.it](v.schiavoni@pm.univpm.it) (V.S.);  \n[d.sartini@univpm.it](d.sartini@univpm.it) (D.S.)  \n3 Advanced Technology Center for Aging Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) INRCA, 60121 Ancona, Italy; [s.fumarola@inrca.it](s.fumarola@inrca.it)  \n4 Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; [a.romagnoli@staff.univpm.it](a.romagnoli@staff.univpm.it)  \n5 Department of Biomedical Sciences and Public Health, Section of Legal Medicine, Polytechnic University of Marche, 60126 Ancona, Italy; [a.montana@univpm.it](a.montana@univpm.it)  \n6 Department of General Surgery and Surgical-Medical Specialties, School of Dentistry, University of Catania, 95124 Catania, Italy; [alessandro.polizzi@phd.unict.it](alessandro.polizzi@phd.unict.it)  \n* Correspondence: [giovanni.tossetta@uniroma5.it](giovanni.tossetta@uniroma5.it) (G.T.); [roberto.campagna@uniroma5.it](roberto.campagna@uniroma5.it) (R.C.)† These authors contributed equally to this work.  \n‡ These authors share last authorship.  \nAbstract  \nCisplatin, a platinum-based compound, is a cornerstone of modern chemotherapy and remains widely used against a variety of solid tumors, including testicular, ovarian, lung, bladder, and head and neck cancers. Its anticancer activity is primarily attributed to the formation of DNA crosslinks, which obstruct replication and repair, ultimately leading to apoptosis. However, the clinical value of cisplatin is constrained by two major challenges: its toxic profile and the development of resistance. Cisplatin toxicity arises from its interaction not only with tumor DNA but also with proteins and nucleic acids in healthy tissues, resulting in a range of adverse effects, including, but not limited to, nephrotoxicity, ototoxicity, neurotoxicity, and gastrointestinal injury. In pediatric patients, permanent hearing loss represents a particularly debilitating complication. On the other hand, tumor cells can evade cisplatin cytotoxicity through diverse mechanisms, including reduced intracellular drug accumulation, enhanced DNA repair, detoxification by thiol-containing molecules, and alterations in apoptotic signaling. These resistance pathways severely compromise treatment outcomes and often necessitate alternative or combination strategies. This review examines the chemical structure of cisplatin, the molecular mechanisms of cisplatin cytotoxicity and cisplatin-induced resistance, as well as the main applications in cancer management and the complications associated with its clinical use.  \nKeywords: cisplatin; cis-diamminedichloroplatinum(II); chemoresistance  \n1. Introduction  \nOver the past several decades, platinum-based chemotherapeutics, particularly cisdiamminedichloroplatinum(II), known as cisplatin (CAS No. 15663-27-1), have emerged as  \npivotal agents in the oncological pharmacopeia due to their robust cyto","cbCaivWnCZ7Whvlx","https://ap.wps.com/l/cbCaivWnCZ7Whvlx","pdf",1222242,28,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What makes cisplatin effective against cancer cells?\",\"answer\":\"Cisplatin forms DNA crosslinks that obstruct DNA replication and repair, leading to apoptosis. This underpins its frontline use in chemotherapy regimens.\"},{\"question\":\"What are the major clinical limitations of cisplatin?\",\"answer\":\"Its toxicity and the development of resistance. Toxicity involves damage to healthy tissues through interactions with proteins and nucleic acids, causing nephrotoxicity, ototoxicity, neurotoxicity, and gastrointestinal injury.\"},{\"question\":\"How do tumor cells develop resistance to cisplatin?\",\"answer\":\"Tumors can reduce intracellular drug accumulation, enhance DNA repair, detoxify cisplatin using thiol-containing molecules, or alter apoptotic signaling. These pathways compromise treatment outcomes and may require alternative or combination strategies.\"}]","Cisplatin as a Xenobiotic Agent - Molecular Mechanisms of Actions and Clinical Applications in Oncology | PDF",1790091712,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8eb443575784ed9429588707e3825be5.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6b2a74d901be850392c3946561b45f4.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/611ddfe6c98fabbb29dc5ca9d9a76d8c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fba1c879faf5a1a738c81d0f317c369.webp",980,1385]